Clinical Differences in Hospitalized Adult Influenza Patients between the A (H1N1) pdm09 and the A (H3N2) Seasons in Japan

Nozomi Oikawa, M. Seki
{"title":"Clinical Differences in Hospitalized Adult Influenza Patients between the A (H1N1) pdm09 and the A (H3N2) Seasons in Japan","authors":"Nozomi Oikawa, M. Seki","doi":"10.4172/2332-0877.1000353","DOIUrl":null,"url":null,"abstract":"To determine the differences in the clinical features of hospitalized elderly patients with influenza between the A (H1N1) pdm09 and the A (H3N2)-dominant seasons, 12 adult patients (mean age, 76.5 years) with influenza who were hospitalized during the 2015-2016 A (H1N1) pdm09-dominant season were compared with 26 adult patients (mean age, 82.5 years) with influenza who were hospitalized during the 2016-2017 A (H3N2)-dominant season. Compared with the A (H3N2)-dominant 2016-2017 season, the A (H1N1) pdm09-dominant 2015-2016 season had fewer non-survivors, but had significantly fewer patients who required oxygenation/respirator support and intravenous anti-influenza agents, such as peramivir. Among the severe patients who received oxygenation/respirator support, the outcomes were better in the A (H3N2)-dominant 2016-2017 season than in the A (H1N1) pdm09-dominant 2015-2016 season. The pneumonia types and detected bacteria did not differ between the two seasons, but the use of sulbactam/ampicillin was more frequent in the A (H1N1) pdm09-dominant 2015-2016 season than in the A (H3N2)-dominant 2016-2017 season. These data suggest that peramivir treatment and oxygenation/respirator support, but not sulbactam/ampicillin administration, may improve the outcome of severe elderly patients hospitalized for influenza, especially the A (H3N2) type.","PeriodicalId":73792,"journal":{"name":"Journal of infectious disease and therapy","volume":"6 1","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2332-0877.1000353","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of infectious disease and therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2332-0877.1000353","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

To determine the differences in the clinical features of hospitalized elderly patients with influenza between the A (H1N1) pdm09 and the A (H3N2)-dominant seasons, 12 adult patients (mean age, 76.5 years) with influenza who were hospitalized during the 2015-2016 A (H1N1) pdm09-dominant season were compared with 26 adult patients (mean age, 82.5 years) with influenza who were hospitalized during the 2016-2017 A (H3N2)-dominant season. Compared with the A (H3N2)-dominant 2016-2017 season, the A (H1N1) pdm09-dominant 2015-2016 season had fewer non-survivors, but had significantly fewer patients who required oxygenation/respirator support and intravenous anti-influenza agents, such as peramivir. Among the severe patients who received oxygenation/respirator support, the outcomes were better in the A (H3N2)-dominant 2016-2017 season than in the A (H1N1) pdm09-dominant 2015-2016 season. The pneumonia types and detected bacteria did not differ between the two seasons, but the use of sulbactam/ampicillin was more frequent in the A (H1N1) pdm09-dominant 2015-2016 season than in the A (H3N2)-dominant 2016-2017 season. These data suggest that peramivir treatment and oxygenation/respirator support, but not sulbactam/ampicillin administration, may improve the outcome of severe elderly patients hospitalized for influenza, especially the A (H3N2) type.
日本A (H1N1) pdm09和A (H3N2)季节住院成人流感患者的临床差异
为确定甲流pdm09和甲流H3N2优势季节住院老年流感患者临床特征的差异,将2015-2016年甲流pdm09优势季节住院的12例成人流感患者(平均年龄76.5岁)与2016-2017年甲流H3N2优势季节住院的26例成人流感患者(平均年龄82.5岁)进行比较。与2016-2017年A (H3N2)为主的流感季相比,2015-2016年A (H1N1) pdm09为主的流感季的非幸存者人数较少,但需要氧配合/呼吸机支持和静脉注射抗流感药物(如帕拉米韦)的患者人数明显减少。在接受氧合/呼吸机支持的重症患者中,2016-2017年以A (H3N2)为主季节的预后优于2015-2016年以A (H1N1) pdm09为主季节的预后。肺炎类型和检测到的细菌在两个季节之间没有差异,但在2015-2016年以A (H1N1) pdm09为主的季节使用舒巴坦/氨苄西林的频率高于2016-2017年以A (H3N2)为主的季节。这些数据表明,帕拉米韦治疗和氧合/呼吸机支持,而不是舒巴坦/氨苄西林治疗,可能改善因流感住院的严重老年患者的预后,特别是A (H3N2)型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信